Eur.- Monograph Tablets -0478-: European Pharmacopoeia -ph.

The monograph dictates that the excipients used must be safe, non-toxic, and must not adversely affect the therapeutic efficacy or bioavailability of the active pharmaceutical ingredient (API). Excipients typically include diluents, binders, disintegrants, glidants, lubricants, and coloring or flavoring agents. Minimizing Microbial Contamination

The monograph begins with a precise definition of what constitutes a "tablet." According to Ph. Eur. 0478, , obtained by compressing uniform volumes of particles or by another suitable manufacturing technique, such as extrusion, moulding or freeze-drying (lyophilisation). European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

The majority of Monograph 0478 is dedicated to mandatory physical tests. Failure in any of these three categories results in batch rejection. The monograph dictates that the excipients used must

The Ph. Eur. monograph for Tablets - 0478 specifies a range of testing requirements to ensure the quality of tablets, including: Failure in any of these three categories results

Tablets must have sufficient strength to resist crumbling or breaking during handling and shipping. This is often assessed via Friability (2.9.7) and Resistance to Crushing (2.9.8) tests.

The , titled "Tablets" (Compressi) , is the central general monograph establishing the mandatory quality standards for all tablet dosage forms in Europe. It provides the legal and scientific framework for their development, production, and marketing. Core Definition & Scope

To ensure every patient gets the exact same dose, tablets must comply with tests for or uniformity of content . 4. Subdivision of Scored Tablets